Skip to main content
  1. Home
    /
  2. IPO
    /
  3. Anlon Healthcare IPO
Anlon Healthcare IPO
7.04xsubscribed

Anlon Healthcare IPO

Pharmaceuticals & Drugs
listed
₹14,104Min. investment

Anlon Healthcare Limited IPO Details

SectorPharmaceuticals & Drugs
Price range₹86.00 – ₹91.00
IPO type
Regular
Lot size164 shares
Issue size₹121Cr
Red Herring Prospectus
Read
Market cap
₹483.68CrLower than sector avg
RevenueApr 2024 - Mar 2025
₹120.29CrLower than sector avg
Growth rate3Y CAGR
2.14%

Anlon Healthcare IPO Subscription Status

Date
QIB
NII
Retail
Total
26-Aug-25
0.73 times (X)
0.66 times (X)
9.11 times (X)
1.7 times (X)
28-Aug-25
0.73X
2.02X
22.4X
3.31X
29-Aug-25
0.82X
10.23X
46.63X
7.04X

As on 26-Aug-25, 5:30 PM

Anlon Healthcare IPO Timeline

  1. Pre-apply
    25 Aug 2025
  2. Bid start
    26 Aug 2025
  3. Bid end
    29 Aug 2025
  4. Allotment
    1 Sep 2025
  5. Release of funds
    2 Sep 2025
  6. Demat transfer
    2 Sep 2025
  7. Listing
    3 Sep 2025

About Anlon Healthcare Limited

Anlon Healthcare is a chemical manufacturing company engaged in the manufacturing of pharma intermediates and active pharmaceutical ingredients (APIs). Its products serve as raw materials and key starting materials for manufacturing APIs and pharmaceutical formulations, including tablets, capsules, ointments, and syrups, as well as ingredients for nutraceuticals, personal care products, and animal health products. The company operates from a single manufacturing facility located in Rajkot, Gujarat. The facility comprises two separate manufacturing blocks for pharmaceutical intermediates and APIs with an aggregate installed production capacity of 400 MTPA, along with four in-house laboratories and storage facilities.
The company’s product portfolio consists of 65 commercialised products, 28 products at the pilot stage, and 49 products at the laboratory testing/laboratory scale stage, totalling 142 products across various categories. This represents substantial growth from 83 total products in FY23 to 142 products in FY25. Its commercialised products include 22 pharmaceutical intermediates, 18 APIs, 20 nutraceutical APIs, 3 personal care products, and 2 animal health products. Key products span across therapeutic categories, including anti-inflammatory (NSAID), analgesic, antipyretic, antihistamine, antidepressant, antipsychotic, anticoagulant, and nutritional supplements.
The company has received Drug Master File (DMF) approvals from major regulatory authorities, including the Brazilian Health Regulatory Agency (ANVISA) for loxoprofen sodium dihydrate, the National Medical Products Administration of China (NMPA) for loxoprofen sodium dihydrate, and the Pharmaceuticals and Medical Devices Agency of Japan (PMDA) for loxoprofen sodium dihydrate and loxoprofen acid. It has filed 21 DMFs with regulatory authorities across the European Union, Russia, Japan, South Korea, Iran, Jordan, and Pakistan.
The company supplies products to both domestic and overseas markets, serving customers in over 15 countries. Their manufacturing facility has been audited and approved by 33 customers and their respective regulatory authorities. It manufactured and sold 338 MT of APIs and pharma intermediates in FY25 to 38 customers, compared to 153 MT to 39 customers in FY24 and 316 MT to 48 customers in FY23. Revenue concentration among the top 10 customers remains high at approximately 77-78% across the 3 fiscal years.
The Indian pharmaceutical industry is ranked the 3rd largest globally by volume and is expected to grow at a CAGR of 10% during FY24-30, reaching INR 7,30,000 crore by FY30. The API market, representing approximately 35% of the pharmaceutical market, is expected to grow at a CAGR of 13.7%, while the nutraceutical market is projected to grow at a 10-12% CAGR over the next few years. Key demand drivers include an ageing population expected to touch 17.3 crore by 2026, higher per capita income improving affordability, increasing penetration of health insurance through Ayushman Bharat, and a sharp rise in lifestyle-related diseases such as diabetes and cardiovascular ailments.
These industry dynamics present strong tailwinds for Anlon Healthcare. The company stands to gain from India’s growing role in global supply chains amid the “China+1” diversification strategy adopted by global pharma players, which is driving sourcing away from China toward Indian manufacturers. Further, rising demand in high-growth categories such as nutraceuticals (10–12% CAGR), veterinary APIs, and personal care APIs provides opportunities for diversification.
Now, Anlon Healthcare Ltd is launching its initial public offering (IPO), which consists of a fresh issue worth up to ₹121.03 crore. The total issue size of the IPO is ₹121.03 crore. Its shares will be listed on the NSE and BSE.

Checklist

Quality analysis
Revenue growth
Company valuation
Earnings expansion
Risk analysis
Debt to Equity ratio
Promoter holdings
Shares pledged
The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily

Strength and Weakness

Diversified product portfolio

Anlon Healthcare boasts a strong portfolio of 65 commercialised products and 28 products at the pilot stage as of March 2025. The product mix covers pharmaceutical intermediates, APIs, nutraceuticals, personal care, and veterinary APIs, serving a wide range of end-user industries. This diversity supports scale and market resilience in domestic and export markets, with 142 products in various development stages.

High capacity utilisation

Operating from a single zero-liquid-discharge facility in Rajkot with 400 MTPA installed capacity, Anlon Healthcare achieved 84.41% capacity utilisation in FY25. Plans are underway to increase installed capacity to 1,100 MTPA with a new plant, aiming to capitalise on demand growth and expand market share.

Leadership in niche APIs

Anlon is among the few Indian manufacturers of loxoprofen sodium dihydrate, holding regulatory DMF approvals in Brazil, China, and Japan, and has filed 21 DMFs globally. This positions the company for robust international growth and regulatory credibility.

High standards in quality assurance

Anlon’s manufacturing is ISO 9001:2015, GMP, and WHO-GMP certified. The facility is regularly audited by over 33 customers and regulatory authorities, evidencing strict global quality adherence and robust compliance systems. Complementing its quality efforts, Anlon Healthcare’s operations are technology-driven and sustainability-oriented, committed to environmental stewardship, and operating a zero liquid discharge (ZLD) manufacturing facility.

Objectives of Anlon Healthcare Limited IPO

Working capital requirements
35.65%
The company will utilise ₹43.15 crore towards the working capital requirements.
General corporate purposes
35.00%
The amount spent towards general corporate purposes shall not exceed 25% of gross proceeds.
Capital expenditure
25.38%
The company will utilise ₹30.72 crore towards capital expenditure for the proposed expansion.
Repayment of loans
4.13%
The company will utilise ₹5.00 crore towards repayment of borrowings.

Compare

CompanyRevenue*3Y growthPATMarket capP/E ratioD/E ratio
This IPO₹120.29Cr2.14%₹20.52Cr₹483.68Cr14.260.73
This sector (avg.)₹1,331.47Cr0%₹193.4Cr₹10,914.84Cr60.870.43
₹52,578.44Cr---₹10,980.1Cr₹3,82,765.9Cr36.980.03
₹9,360Cr---₹2,191Cr₹1,60,635Cr64.600
₹11,516.09Cr---₹1,911.25Cr₹1,34,051.5Cr62.640.42

*Revenue for financial year 2024-25. Lower P/E and D/E ratios are generally preferred.

Anlon Healthcare IPO Contact Details

Company NameAnlon Healthcare Limited

How to apply for Anlon Healthcare IPO?

  1. Step 1

    Log in to your Upstox account to access IPO investments. Next, select the current IPO section.

  2. Step 2

    Specify IPO details. Enter the number of lots and the price you wish to apply for.

  3. Step 3

    Enter UPI ID. After entering your UPI ID, click submit. This will place your bid with the exchange.

  4. Step 4

    Mandate Notification. Your UPI app will receive a mandate notification to block funds.

  5. Step 5

    Approve Request. Your funds will be blocked once you approve the mandate request on your UPI.

Anlon Healthcare Limited IPO FAQs

Investors can apply for the Anlon Healthcare IPO through their Demat account via the stock exchange or through their broker.
The issue size of the Anlon Healthcare IPO is 121 Cr.
Pre-applying for an IPO allows you to submit your application before the official subscription period begins.
The IPO shares will typically list on major stock exchanges such as the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE), as specified in the IPO prospectus.
Anlon Healthcare IPO will be open between 2025-08-26 and 2025-08-29.
Anlon Healthcare IPO allotment date is 2025-09-02. For Anlon Healthcare IPO allotment status check, you can visit the website of the registrar of the IPO.
For Anlon Healthcare IPO, the IPO registrar is KFin Technologies Limited. You can check Anlon Healthcare IPO allotment status on the website of the registrar.
The shares are proposed to be listed on the BSE and NSE.
The Anlon Healthcare IPO shares will typically be credited to your demat account one working day before the IPO's listing date, provided your application is successfully allotted.
The Anlon Healthcare IPO lot size is 164 and minimum order quantity is 164.
Anlon Healthcare IPO has set the price band for its IPO at 91 per equity share with a face value of 10.